Author

Philip L. Cyr

P Cyr, P. Cyr, P.L. Cyr, PHILIP L. CYR, Philip Cyr, Philip L Cyr, Philip L. Cyr, YESCARTA™) is a chimeric antigen receptor (CAR) T-cell therapy approved in the U.S. for adult patients with R/R-LBCL after two or more lines of chemotherapy. Axi-cel has demonstrated favorable outcomes in this population with an on-going complete response (CR) rate of 40% and a median OS not yet reached with a minimum of 12 months follow-up (Neelapu